Crinetics Pharmaceuticals Liabilities 2024

Crinetics Pharmaceuticals Aktienanalyse

What does Crinetics Pharmaceuticals do?

Crinetics Pharmaceuticals Inc. is a leading biopharmaceutical company specializing in the development and commercialization of innovative therapies for rare endocrine diseases and hormone-dependent tumors. The company was founded in 2008 by a team of experienced pharmacy professionals and is headquartered in San Diego, California. History Crinetics Pharmaceuticals was founded based on groundbreaking research in the field of endocrine diseases. The company aims to develop innovative therapies for rare endocrine diseases and hormone-dependent tumors that have been inadequately treated thus far. Crinetics draws on decades of experience and in-depth knowledge in the fields of endocrinology, neuroscience, and cancer research. Business model Crinetics is a research and development company specializing in the discovery, development, and commercialization of drugs for rare endocrine diseases. The company has an extensive portfolio of proprietary compounds based on novel mechanisms of action that are in various stages of development. Crinetics works closely with leading experts in the field of endocrinology and oncology to develop and commercialize groundbreaking new therapies. Different divisions Crinetics specializes in the research, development, and commercialization of products that can be used in rare endocrine diseases and hormone-dependent tumors. The company operates in various areas, including: - Acromegaly: Crinetics is developing a medication for the treatment of acromegaly, a rare disease caused by overproduction of growth hormone. - Cushing's syndrome: Crinetics is developing a medication for the treatment of Cushing's syndrome, a rare disease caused by overproduction of cortisol. - Hypoparathyroidism: Crinetics is developing a medication for the treatment of hypoparathyroidism, a rare disease characterized by insufficient production of parathyroid hormone. - Neuroendocrine tumors: Crinetics is developing a medication for the treatment of neuroendocrine tumors, a rare group of tumors that arise from neuroendocrine cells. Products Crinetics has an extensive portfolio of innovative products based on novel mechanisms of action that are in various stages of development. The company focuses on developing drugs that can be used in rare endocrine diseases and hormone-dependent tumors. Some of the notable products are: - CRN00808: CRN00808 is a medication that can help improve the body's monitoring system that regulates the release of growth hormones. It is currently in phase 2 clinical trials. - CRN01941: CRN01941 is a medication for the treatment of Cushing's syndrome. It has been developed to inhibit excessive production of cortisol and is currently in phase 2 clinical trials. - CRN04777: CRN04777 is a medication for the treatment of acromegaly. It has been developed to inhibit overproduction of growth hormone and is currently in phase 1 clinical trials. - CRN04894: CRN04894 is a medication for the treatment of hypoparathyroidism. It has been developed to stimulate parathyroid hormone production and is currently in phase 1 clinical trials. Conclusion Crinetics Pharmaceuticals is a leading biopharmaceutical company specializing in the development of innovative therapies for rare endocrine diseases and hormone-dependent tumors. The company has an extensive portfolio of proprietary compounds based on novel mechanisms of action that are in various stages of development. Crinetics works closely with leading experts in the field of endocrinology and oncology to develop and commercialize groundbreaking new therapies. Crinetics Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Crinetics Pharmaceuticals's Liabilities

Crinetics Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Crinetics Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Crinetics Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Crinetics Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Crinetics Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Crinetics Pharmaceuticals Stock

What is the level of liabilities of Crinetics Pharmaceuticals this year?

Crinetics Pharmaceuticals has a debt balance of 96.25 M USD this year.

What were the liabilities of Crinetics Pharmaceuticals compared to the previous year?

The liabilities of Crinetics Pharmaceuticals have increased by 168.85% increased compared to the previous year.

What are the consequences of high debt for investors of Crinetics Pharmaceuticals?

High liabilities can pose a risk for investors of Crinetics Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Crinetics Pharmaceuticals?

Low liabilities mean that Crinetics Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Crinetics Pharmaceuticals affect the company?

An increase in liabilities of Crinetics Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Crinetics Pharmaceuticals affect the company?

A decrease in the liabilities of Crinetics Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Crinetics Pharmaceuticals?

Some factors that can influence the liabilities of Crinetics Pharmaceuticals include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Crinetics Pharmaceuticals so important for investors?

The liabilities of Crinetics Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Crinetics Pharmaceuticals take to modify the liabilities?

To change its liabilities, Crinetics Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Crinetics Pharmaceuticals pay?

Over the past 12 months, Crinetics Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Crinetics Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Crinetics Pharmaceuticals?

The current dividend yield of Crinetics Pharmaceuticals is .

When does Crinetics Pharmaceuticals pay dividends?

Crinetics Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Crinetics Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Crinetics Pharmaceuticals located?

Crinetics Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Crinetics Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Crinetics Pharmaceuticals from 6/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/20/2024.

When did Crinetics Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/20/2024.

What was the dividend of Crinetics Pharmaceuticals in the year 2023?

In the year 2023, Crinetics Pharmaceuticals distributed 0 USD as dividends.

In which currency does Crinetics Pharmaceuticals pay out the dividend?

The dividends of Crinetics Pharmaceuticals are distributed in USD.